Latest period
$1.68B
YoY change
-10.7%
5Y CAGR
+5.7%
Peak year (2024)
$1.88B
Latest annual
$1.68B
Total Liabilities history chart for Insulet (PODD) from 2002 to 2025
Latest: $1.68B
Total Liabilities growth chart for Insulet (PODD) from 2002 to 2025
Latest: -10.7%
Total Liabilities history table for Insulet (PODD) from 2002 to 2025
| 2025 | $1.68B | -10.7% | −$200.90M | ||
| 2024 | $1.88B | +1.1% | +$20.60M | ||
| 2023 | $1.86B | +4.6% | +$80.80M | ||
| 2022 | $1.77B | +18.9% | +$282.20M | ||
| 2021 | $1.49B | +17.6% | +$223.20M | ||
| 2020 | $1.27B | +19.0% | +$202.30M | ||
| 2019 | $1.07B | +48.9% | +$350.36M | ||
| 2018 | $716.64M | +8.9% | +$58.42M | ||
| 2017 | $658.23M | +67.3% | +$264.73M | ||
| 2016 | $393.50M | +63.2% | +$152.42M | ||
| 2015 | $241.07M | +10.4% | +$22.75M | ||
| 2014 | $218.33M | +33.6% | +$54.97M | ||
| 2013 | $163.36M | +6.2% | +$9.47M | ||
| 2012 | $153.88M | +11.4% | +$15.70M | ||
| 2011 | $138.19M | +53.5% | +$48.19M | ||
| 2010 | $90.00M | -24.2% | −$28.79M | ||
| 2009 | $118.79M | +13.2% | +$13.84M | ||
| 2008 | $104.95M | +172.9% | +$66.49M | ||
| 2007 | $38.47M | -75.8% | −$120.44M | ||
| 2006 | $158.91M | +91.7% | +$76.02M | ||
| 2005 | $82.88M | +15.7% | +$11.25M | ||
| 2004 | $71.63M | +101.2% | +$36.02M | ||
| 2003 | $35.61M | -1.5% | −$556.00K | ||
| 2002 | $36.16M | — | — |
- 2025$1.68B-10.7%
- 2024$1.88B+1.1%
- 2023$1.86B+4.6%
- 2022$1.77B+18.9%
- 2021$1.49B+17.6%
- 2020$1.27B+19.0%
- 2019$1.07B+48.9%
- 2018$716.64M+8.9%
- 2017$658.23M+67.3%
- 2016$393.50M+63.2%
- 2015$241.07M+10.4%
- 2014$218.33M+33.6%
- 2013$163.36M+6.2%
- 2012$153.88M+11.4%
- 2011$138.19M+53.5%
- 2010$90.00M-24.2%
- 2009$118.79M+13.2%
- 2008$104.95M+172.9%
- 2007$38.47M-75.8%
- 2006$158.91M+91.7%
- 2005$82.88M+15.7%
- 2004$71.63M+101.2%
- 2003$35.61M-1.5%
- 2002$36.16M—
Total Liabilities values are taken from Insulet's reported balance sheets (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
About Total Liabilities at Insulet (PODD)
According to Insulet's latest reported financial statements, the company's latest reported total liabilities is $1.68B. Total liabilities sum everything the company owes at the end of each reporting period — accounts payable, accrued expenses, debt, lease obligations, and other claims — as filed on the balance sheet. Compare with total assets and total equity for solvency context.
Headline figure above is from the reporting period ending (reported ). Chart and table below cover the full reported history back to .
In 2025, Insulet (PODD) total liabilities totalled $1.68B – declined 10.7% year-over-year.
Across 2020–2025 (5 years), Insulet total liabilities produced a CAGR of +5.7% – with mixed annual results across the window.
The highest annual total liabilities of $1.88B was reported in 2024. The lowest in the available history was $35.61M in 2003.
Insulet Total Liabilities by Year
Insulet Total Liabilities 2025: $1.68B
2025's total liabilities for Insulet came in at $1.68B, declined 10.7% below 2024.
Insulet Total Liabilities 2024: $1.88B
Insulet posted total liabilities of $1.88B in 2024, edged up 1.1% from 2023. This figure represents the highest annual value in the available history.
Insulet Total Liabilities 2023: $1.86B
In 2023, Insulet reported total liabilities of $1.86B, edged up 4.6% from 2022.
Insulet Total Liabilities 2022: $1.77B
Insulet total liabilities in 2022 was $1.77B, grew 18.9% from 2021.
Insulet Total Liabilities 2021: $1.49B
Insulet total liabilities in 2021 was $1.49B.
See more financial history for Insulet (PODD).
Sector peers by Total Liabilities
Healthcare peers of Insulet (PODD), ranked by their latest total liabilities
| $207.88B | |
| $137.19B | |
| $117.67B | |
| $85.94B | |
| $84.20B | |
| $81.93B | |
| $65.36B | |
| $54.86B |
- $207.88B
- $137.19B
- $117.67B
- $85.94B
- $84.20B
- $81.93B
- $65.36B
- $54.86B
Frequently asked questions
Insulet (PODD) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation